Testing a new influenza vaccine that uses less antigen and can be deployed quickly.
Official title: Advanced testing of a hexavalent adjuvanted influenza vaccine platform for dose sparing, multiplexing, and rapid deployment
Funded at Pop Biotechnologies, INC · NIH-11099904 · Data updated 2026-11-12
This study is testing a new type of flu vaccine that uses tiny particles to boost your immune response, so you can get better protection against different flu strains with smaller doses, making it easier to use during outbreaks.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Pop Biotechnologies, INC NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project start | June 1, 2024 |
| Project end | May 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $949,201 |
| NIH project number | 5R44AI181479-02 |
| Project ID | NIH-11099904 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at high risk for influenza complications, such as the elderly, young children, and those with underlying health conditions.
✕Less likely to help
Patients who are not at risk for influenza or those who have already received a different influenza vaccine may not benefit from this research.
What this research studies
This research focuses on developing an innovative influenza vaccine platform that combines multiple protective components to enhance immune response while using lower doses of the vaccine. The approach involves creating lipid bilayer nanoliposomes that carry important viral proteins, which stimulate the immune system more effectively. By using a unique formulation, the vaccine aims to provide better protection against various strains of influenza, including H1N1 and H3N2. Patients may benefit from a more effective vaccine that can be rapidly deployed during outbreaks.
Why it matters
Potential benefit: If successful, this research could lead to a more effective and efficient influenza vaccine that requires less antigen and can be quickly distributed during flu seasons or pandemics.
How similar studies have gone: Other research has shown promise in developing nanoparticle-based vaccines, indicating that this approach could be effective.
Where this research is happening
-
Pop Biotechnologies, INC
Buffalo, United States Active
Researchers
- Principal investigator: Kutscher, Hilliard — Pop Biotechnologies, INC
- Study coordinator: Kutscher, Hilliard
Related research
Other NIH-funded projects on the same topics.
-
Creating vaccines for influenza and other infectious diseases
This study is all about creating new vaccines to help protect people from the flu and other infections, so patients can look forward to better options for staying healthy.
-
Creating vaccines for human trials against influenza and other infectious diseases
This study is working on creating new vaccines to help protect people from flu and other infectious diseases, including those that could be used in harmful situations, so that everyone can have safer and more effective options to stay healthy.
-
Understanding flu and COVID-19 vaccine responses in people and in the lab
Researchers at Stanford explore how flu and COVID-19 vaccines work in people and in lab tests to improve protection for adults.
-
Surveillance and preparedness for flu and other respiratory pathogens in Kenya
A US-based research grant aims to improve how Kenya detects and prepares for influenza and other respiratory diseases to protect people there and global health.
-
Enhanced Seasonal Influenza Vaccine Targeting Shared and Variable Viral Antigens
A new DNA-based influenza vaccine approach aims to provide both precise protection against circulating strains and broader defense against unexpected strains.
-
How the immune system responds to flu shots and flu infection
This project looks at how adults' immune systems react after flu shots or when they catch the flu to find why some people get better protection than others.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.